Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19

How to Cite

OrthoEvidence. Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19. ACE Report. 2021;12(1):1. Available from: https://myorthoevidene.com/AceReport/Report/13267

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:1

The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial

Eur J Integr Med. 2021 Feb; 42: 101305.

Contributing Authors: Z Luo W Chen M Xiang H Wang W Xiao C Xu Y Li J Min Q Tu

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty patients with severe COVID-19 were randomized to receive routine care plus intravenous Xuebijing injection (n=30) or routine care alone (n=30) for the suppression of inflammatory response and management of symptoms. The primary outcome of interest was peripheral blood lymphocyte and interleukin (IL)-6 levels which were measured at 1, 7 and 14 days follow-up. Secondary outcomes of interest in...